Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2016-05-26

Clinical Trial Update: Open-Label Extension Study to Evaluate Long Term Safety and Treatment Effect of DiaPep277® [Phase 3]

View source ↗

Summary

Open-label extension Phase 3 trial of DiaPep277 for Type 1 diabetes was terminated; results were posted on 2016-05-26.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • DiaPep277 (DiaPep277)

Snippet

Sponsor: Andromeda Biotech Ltd. | Conditions: Type 1 Diabetes | Phase 3 | Status: TERMINATED | Results posted: 2016-05-26